Fulcrum Therapeutics FULC

$ 3.63 -0.28%

Quarterly report 2024-Q2
added 07-31-2024

Fulcrum Therapeutics Financial Statements 2011-2024 | FULC

Annual Financial Statements Fulcrum Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	637 K	217 K	626 K	327 M	377 M	-	-	-	-	-	-	-	-
Shares	61.3 K	45 K	35.4 K	27.9 M	22.7 M	-	-	-	-	-	-	-	-
Historical Prices	10.4	4.83	17.7	11.7	16.6	-	-	-	-	-	-	-	-
Net Income	-97.3 M	-110 M	-80.8 M	-70.8 M	-82.7 M	-32.6 M	-23 M	-	-	-	-	-	-
Revenue	2.8 M	6.34 M	19.2 M	8.82 M	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-111 M	-113 M	-81.1 M	-71.6 M	-84.2 M	-33.5 M	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-108 M	-110 M	-78.5 M	-69.2 M	-82.2 M	-32.2 M	-22.3 M	-	-	-	-	-	-
Operating Expenses	113 M	119 M	100 M	80.4 M	84.2 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	41.7 M	41.7 M	30.5 M	21.4 M	13.1 M	8.31 M	4.5 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Fulcrum Therapeutics

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	62.2 M	62 K	61.9 M	61.8 K	61.8 M	59.7 K	52.1 M	46.2 K	40.9 K	40.6 K	40.6 M	36.6 K	32.6 K	31.5 M	27.9 M	27.3 K	23.9 K	22.7 K	22.7 M	17.8 K	1.79 K	1.64 K	1.59 M	1.34 K	1.19 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	55.4 M	-26.9 M	-	-24 M	-23.8 M	-24.8 M	-	-23.7 M	-34.1 M	-25.9 M	-	-20.7 M	-19.6 M	-17 M	-	-19 M	-15.7 M	-18.5 M	-	-16.5 M	-13.2 M	-36.8 M	-	-8.94 M	-7.85 M	-6.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	80 M	-	-	759 K	880 K	295 K	-	1.18 M	1.88 M	2.59 M	-	7.8 M	4.38 M	4.79 M	-	1.85 M	2 M	750 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	52.5 M	-29.8 M	-	-27.4 M	-27.3 M	-27.9 M	-	-24.4 M	-34.2 M	-26 M	-	-20.8 M	-19.7 M	-17 M	-	-19.1 M	-15.9 M	-18.8 M	-	-17 M	-13.5 M	-37.2 M	-	-9.09 M	-7.85 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	52.9 M	-29.4 M	-	-26.9 M	-26.7 M	-27.4 M	-	-23.8 M	-33.5 M	-25.5 M	-	-20.2 M	-19 M	-16.4 M	-	-18.6 M	-15.3 M	-18.3 M	-	-16.5 M	-13 M	-36.7 M	-	-8.69 M	-7.65 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	27.5 M	29.8 M	-	28.2 M	28.2 M	28.2 M	-	25.5 M	36.1 M	28.6 M	-	25.7 M	24.1 M	21.8 M	-	21 M	17.9 M	19.5 M	-	17 M	13.5 M	37.2 M	-	9.09 M	7.85 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	10.2 M	10.1 M	-	9.96 M	10.3 M	11.5 M	-	9.71 M	11.1 M	10.8 M	-	8.63 M	6.68 M	5.5 M	-	5.31 M	5.15 M	5.06 M	-	3.51 M	2.63 M	2.6 M	-	2.12 M	2.06 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency